Drug Profile
Research programme: telomerase inhibitors - Morphochem/Nxera Pharma
Alternative Names: SOT-095; Telomerase inhibitors research programme - Morphochem/Nxera PharmaLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Morphochem AG; Sosei
- Developer Morphochem AG; Nxera Pharma
- Class Macrocyclic compounds; Oxazoles
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer